대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지
DOI QR코드

DOI QR Code

요통을 동반한 MDS 환자에 대한 관리 1례

A Case Report of a Patient with Myelodysplastic Syndrome Who Has Lower Back Pain

  • 주성희 (경희대학교 대학원 임상한의학과) ;
  • 배정한 (경희대학교 한의과대학 간계내과학교실) ;
  • 안소연 (경희대학교 대학원 임상한의학과) ;
  • 장은경 (경희대학교 한의과대학 간계내과학교실) ;
  • 이장훈 (경희대학교 한의과대학 간계내과학교실) ;
  • 김영철 (경희대학교 한의과대학 간계내과학교실)
  • Joo, Seong-hee (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University) ;
  • Bae, Jung-han (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • An, So-yeon (Dept. of Clinical Korean Medicine, Graduate School, Kyung Hee University) ;
  • Jang, Eun-gyeong (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Lee, Jang-hoon (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University) ;
  • Kim, Young-chul (Dept. of Internal Medicine, College of Korean Medicine, Kyung Hee University)
  • 투고 : 2018.03.19
  • 심사 : 2018.05.27
  • 발행 : 2018.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: This case aims to describe management of a patient with myelodysplasitc syndrome who has lower back pain. Methods: A 75-year-old female patient with myelodysplasitc syndrome was hospitalized from February 28, 2018 to March 14, 2018. The patient was treated with Azacitidine at Bundangjyesaeng Hospital, and lower back pain worsened without any reason. The patient was willing to undergo traditional Korean medical treatment, and Wonyuksayuk-tang was chosen considering both hematopoiesis dysfunction and lower back pain. Results: The patient was diagnosed with myelodysplatic syndrome after bone marrow aspiration and biopsy at Bundangjyesaeng Hospital. After the Wonyuksayuk-tang treatment, platelet levels increased about 50% compared with initial blood test results. In addition, lower back pain and general weakness were slightly improved. Conclusion: It is important to manage the quality of life of patients with myelodysplastic syndrome. This case suggests that traditional Korean medicine has a beneficial effect on the management of myelodysplastic syndrome.

키워드

참고문헌

  1. Germing U, Kobbe G, Haas, R, Gattermann N. Myelodysplastic Syndromes: Diagnosis, Prognosis, and Treatment. Deutsches Arzteblatt International 2013;110(46):783-90.
  2. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematology Oncology Clinics of North America 2010;24(2):287-94. https://doi.org/10.1016/j.hoc.2010.02.011
  3. Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the Dusseldorf MDS-registry. Leukemia Research 2011; 35(12):1591-6. https://doi.org/10.1016/j.leukres.2011.06.001
  4. Montalban-Bravo G, Gracia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. American Journal of Hematology 2018;93(1):129-47. https://doi.org/10.1002/ajh.24930
  5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120(12):2454-65. https://doi.org/10.1182/blood-2012-03-420489
  6. Klepin HD. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clinics in Geriatric Medicine 2016;32(1):155-73. https://doi.org/10.1016/j.cger.2015.08.010
  7. Kim JD. A case of myelodysplastic syndrome. Journal of Internal Korean Medicine 1999;20(1) :274-9.
  8. Kim JY, Joung JY, Son CG, Cho JH. Well-Managed Myelodysplastic Syndrome Patients Treated with Traditional Korean Medicine; Report of Two Cases. Journal of Internal Korean Medicine 2016;37(3) :539-47.
  9. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology 2012;30(27):3376-82. https://doi.org/10.1200/JCO.2011.40.7379
  10. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. American journal of hematology 2016;91(1) :76-89. https://doi.org/10.1002/ajh.24253
  11. Kim WH, Choi DY. Jangbubyeonzhengryonchi. Seoul: Seongbosa; 1985, p. 57-9, 63-5.
  12. Park SM, Kim YC, Lee JH, Woo HJ. Effects of Juakium-derivative on Hematopoietic Effects. Journal of Internal Korean Medicine 2002; 23(2):212-21.
  13. The faculty of Kyunghee university Korean medicine hospital. Kyungheehanbangcheobangjip. Seoul: Kyunghee university Korean medicine hospitial; 2007, p. 288.
  14. Shin JY. Explanation of Bangyakhappyun. Seoul: Sungbosa; 1988, p. 62.
  15. Schiffer CA, Bohlke K, Delaney M, Hume H, Maqdalinski AJ, McCullough JJ, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology 2018;36(3):283-99. https://doi.org/10.1200/JCO.2017.76.1734
  16. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modeification of the International Working Group(IWG) response criteria in myelodysplasia. Blood 2006;108(2): 419-25. https://doi.org/10.1182/blood-2005-10-4149